VYJUVEK cash funds a wider gene therapy platform
- Krystal reported $119.2 million of Q2 2026 net product revenue, all from VYJUVEK.
- U.S. revenue reached $91.6 million, while European sales flattened sequentially due to German pricing reserves.
- The UK approved VYJUVEK in May 2026, expanding the global commercial footprint.
- The biggest near-term pipeline readout is KB803 in ocular DEB, expected before year-end 2026.
- FDA platform technology designations make the pipeline less dependent on one drug over time.
From one product to a platform
Krystal is still a VYJUVEK story today. The company reported $119.2 million of Q2 2026 net product revenue, and all of it came from that one product. That concentration is real, but the launch is scaling outside the US, aided by a new UK authorization in May 2026.
The bull case is that VYJUVEK can fund the next wave. Krystal owns its HSV-1 gene delivery platform, its manufacturing, and its worldwide rights. The FDA has granted platform technology designations to KB407, KB111, and KB801, which may cut risk, cost, and time for later programs because the agency can rely on shared platform data.
The next proof point is pipeline data. KB803, an eye drop form for ocular DEB, completed Phase 3 IOLITE enrollment in April 2026, with top-line results expected before year-end 2026. The oncology pipeline also expanded with intratumoral KB707 now evaluating Gorlin syndrome.
The bear case is timing and price. Germany pricing is expected in late 2026 and caused a revenue reserve provision in Q2. In the US, some patients are moving to a start-stop maintenance pattern, which can make quarterly revenue harder to read. If VYJUVEK slows before another product is approved, the stock may have less room for error.
A gene therapy gel business
Krystal makes money by selling genetic medicines. Its only commercial product is VYJUVEK, a topical gel for dystrophic epidermolysis bullosa, or DEB. DEB is a rare disease where skin can blister and wound easily because the body lacks working collagen VII.
VYJUVEK is important because it is redosable. Many gene therapies are one-time treatments, but VYJUVEK can be applied again to wounds. That gives Krystal a recurring treatment model, not just a one-shot sale.
The company is vertically integrated, which means it runs the chain from research through manufacturing and commercialization. That can help in gene therapy, where making the product is hard. It also means a plant problem could hit supply, clinical trials, and launches at the same time.
Krystal owns exclusive worldwide rights to its products. This keeps more economics in-house, but it also puts more work on the company as it expands in Europe, Japan, and the UK.
One seller, many shots
VYJUVEK
VYJUVEK is the sole commercial product. It is approved in the US, Europe, Japan, and the UK for DEB and produced all $119.2 million of Q2 2026 net product revenue.
KB803
KB803 is an eye drop form of VYJUVEK for ocular DEB. Phase 3 IOLITE enrollment finished in April 2026, with top-line results expected before year-end 2026.
KB407
KB407 is an inhaled gene therapy for cystic fibrosis. Krystal is running a repeat-dose safety study to enable a registrational trial start in 2027.
KB801
KB801 targets neurotrophic keratitis, a serious eye disease that can damage the cornea. The EMERALD-1 registrational study is enrolling, with top-line data expected early 2027.
KB707
KB707 is an immunotherapy for solid tumors. The program spans an inhaled formulation for non-small cell lung cancer and an intratumoral application in Gorlin syndrome.
KB408 and KB111
KB408 targets alpha-1 antitrypsin deficiency, while KB111 targets Hailey-Hailey disease. Both test whether Krystal's HSV-1 platform can work beyond skin wounds.
KB304
KB304 sits inside the Jeune Aesthetics subsidiary and targets décolleté wrinkles. A Phase 2 study is expected to start in 2027.
VYJUVEK is the business today
Krystal reports one operating segment. For Q2 2026, global revenue was $119.2 million, all from VYJUVEK. The US contributed $91.6 million, while Europe and Japan added $27.6 million.
What could break the thesis
One-product dependence
High impact · High oddsKrystal's commercial revenue still comes from VYJUVEK. If demand slows, payer access tightens, or patient use drops, the pipeline may not be ready to replace that growth. This matters most before KB803 or another program can become a second approved product.
Maintenance dosing lumpiness
Medium impact · Medium oddsManagement has noted that US revenue is affected by patients moving into a start-stop maintenance cadence. Some patients may not need steady treatment every quarter. The disease burden has not changed, but revenue timing could get harder to predict.
International pricing risk
High impact · Medium oddsEurope and Japan generate important revenue, but final pricing in Germany is expected in the second half of 2026. A reserve provision for these negotiations caused European sequential revenue to flatten in Q2. Weak final terms could lower the long-term value of those markets and influence other countries.
Pipeline delay or failure
High impact · Medium oddsThe platform story depends on more than VYJUVEK. KB803, KB407, KB801, KB408, and KB707 all still need clinical and regulatory success. A failure or delay in any major trial could hurt confidence in the wider platform.
Manufacturing disruption
High impact · Low oddsKrystal makes complex biologic products in-house. That control is a strength when things run well. A quality issue, delay, or capacity problem could hurt VYJUVEK supply and slow clinical trials.
Drug pricing politics
Medium impact · Medium oddsKrystal sells high-cost genetic medicines, so pricing policy matters. Executive orders and proposed legislation on drug pricing reform create uncertainty. Even without a new law, payer pressure can change access and net price.
In one breath
What does Krystal Biotech actually sell?
Krystal sells VYJUVEK, a topical redosable gene therapy gel for DEB wounds. In Q2 2026, all $119.2 million of net product revenue came from VYJUVEK.
Why is the HSV-1 platform important?
Krystal uses an engineered herpes simplex virus-1, or HSV-1, to deliver genes into cells. FDA platform technology designations for KB407, KB111, and KB801 suggest the agency may let Krystal reuse parts of its platform data across programs.
What is the next big catalyst for KRYS?
The clearest near-term catalyst is top-line data from the Phase 3 IOLITE study of KB803 in ocular DEB, expected before year-end 2026. Resolution of German pricing negotiations in late 2026 is another key event.
What is the main risk for KRYS stock?
The main risk is that Krystal still depends on one commercial product. If VYJUVEK revenue becomes choppy or slows before another product is approved, the platform story may not be enough to support expectations.
